Tuesday, November 12, 2024 11:53:17 AM
TWEET
SOHM, Inc.
@sohminc
We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks.
The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying. We continue to explore new opportunities and are organizing several lunch-and-learn sessions throughout the fourth quarter to prepare for revenue growth in 2025.
SOHM, Inc.
@sohminc
We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks.
The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying. We continue to explore new opportunities and are organizing several lunch-and-learn sessions throughout the fourth quarter to prepare for revenue growth in 2025.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
